Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Bramstedt – page 93

1 461 clinical trials in Bad Bramstedt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bramstedt at a glance
1 461
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 461 trials in Bad Bramstedt

Open in trial search

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:AstraZeneca AB

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Eli Lilly & Co.

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Not recruiting

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Study on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:F. Hoffmann-La Roche AG

Hepatic cancer+1

Not recruiting

Study on Atezolizumab for Patients with Lung and Liver Cancer Using Digital Health Solutions

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Bramstedt

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on systemic sclerosis treatment, investigating a novel subcutaneous therapy aimed at reducing skin sclerosis symptoms. These trials are evaluating new therapeutic approaches for managing this challenging autoimmune condition.

  • Skin sclerosis management
  • Subcutaneous administration methods
  • Novel therapeutic compounds

The research emphasizes improving treatment options for patients with progressive skin hardening and tissue fibrosis.

02 Rare Blood Disorders

Clinical investigations targeting Hypereosinophilic Syndrome, examining the effectiveness of new subcutaneous treatments for patients with uncontrolled disease states while maintaining standard care protocols.

  • Blood disorder management
  • Treatment resistance
  • Standard of care optimization

These studies aim to provide better therapeutic options for patients with rare eosinophilic conditions.

03 Inflammatory Conditions

Advanced research into systemic lupus erythematosus treatment, focusing on disease activity reduction and exploring new therapeutic compounds for this complex autoimmune disorder.

  • Disease activity assessment
  • Treatment safety evaluation
  • Long-term efficacy monitoring

The studies employ comprehensive assessment tools to measure treatment effectiveness in lupus patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.